Expert Interview
Discussing the Phase 1b Clinical Trial Results for ENV-294 in Patients with moderate-to-severe Atopic Dermatitis from Enveda Biosciences
Ticker(s): ENVEDA BIOSCIENCES, SNY, ABBV, PFE, INCY, LLY, ARQTInstitution: Dermatology Associates of Western Connecticut
- Assistant Clinical Professor of Dermatology in the Yale University School of Medicine, dermatology specialist at private practice.
- Treats 500 patients with atopic dermatitis annually
- Professional special interests include the treatment of skin cancer and pediatric dermatology.
How are you currently managing patients with moderate-to-severe atopic dermatitis, and what unmet needs remain despite available biologics and oral JAK inhibitors?
Added By: sara_adminWhat is your interpretation of the Phase 1b ENV-294 results, including the reported EASI reductions, EASI-75/EASI-90 rates, and vIGA-AD outcomes?
Added By: sara_adminHow do you view the potential clinical relevance of ENV-294’s once-daily oral, non-kinase mechanism compared with approved injectable biologics or oral JAK inhibitors?
Added By: sara_adminWhich patient populations may be most appropriate for ENV-294 if later-stage data are positive, considering disease severity, prior therapy exposure, comorbid atopic disease, and safety concerns?
Added By: sara_adminWhat factors, such as long-term safety, durability of response, speed of onset, monitoring requirements, or access/reimbursement, would most influence your willingness to adopt ENV-294 in clinical practice?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
